Evonik to build new lipid production facility for mRNA-based therapies in U.S.
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
This agreement is in addition to the $92 million filling line expansion announced in November 2021
Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults
Bioanalytical approach to accelerate development efforts in the identification of compounds that can treat chlorine or sulfur mustard injuries
New interim data from these studies demonstrate that a booster dose of the Johnson & Johnson Covid-19 vaccine generated a rapid and robust increase in spike-binding antibodies, nine-fold higher than 28 days after the primary single-dose vaccination.
Subscribe To Our Newsletter & Stay Updated